| Literature DB >> 24795711 |
Audrey Charlebois1, Mario Jacques1, Marie Archambault1.
Abstract
Clostridium perfringens is an opportunistic pathogen that can cause food poisoning in humans and various enterotoxemia in animal species. Very little is known on the biofilm of C. perfringens and its exposure to subminimal inhibitory concentrations of antimicrobials. This study was undertaken to address these issues. Most of the C. perfringens human and animal isolates tested in this study were able to form biofilm (230/277). Porcine clinical isolates formed significantly more biofilm than the porcine commensal isolates. A subgroup of clinical and commensal C. perfringens isolates was randomly selected for further characterization. Biofilm was found to protect C. perfringens bacterial cells from exposure to high concentrations of tested antimicrobials. Exposure to low doses of some of these antimicrobials tended to lead to a diminution of the biofilm formed. However, a few isolates showed an increase in biofilm formation when exposed to low doses of tylosin, bacitracin, virginiamycin, and monensin. Six isolates were randomly selected for biofilm analysis using scanning laser confocal microscopy. Of those, four produced more biofilm in presence of low doses of bacitracin whereas biofilms formed without bacitracin were thinner and less elevated. An increase in the area occupied by bacteria in the biofilm following exposure to low doses of bacitracin was also observed in the majority of isolates. Morphology examination revealed flat biofilms with the exception of one isolate that demonstrated a mushroom-like biofilm. Matrix composition analysis showed the presence of proteins, beta-1,4 linked polysaccharides and extracellular DNA, but no poly-beta-1,6-N-acetyl-D-glucosamine. This study brings new information on the biofilm produced by C. perfringens and its exposure to low doses of antimicrobials.Entities:
Keywords: Clostridium perfringens; anaerobes; antibiotic prophylaxis; anticoccidials; biofilm formation; biofilms; low dose antibiotics
Year: 2014 PMID: 24795711 PMCID: PMC4001024 DOI: 10.3389/fmicb.2014.00183
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Clostridium perfringens selected isolates and their MIC (μg/mL) to the antibiotics and anticoccidials tested in this study.
| MIC (μg/mL) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Species | Strains | Origin | Biofilm formation | Bacitracin | Virginiamycin | Penicillin | Tylosin | Lincomycin | Salinomycin | Narasin | Monensin | Source |
| Poultry | c1261_A | Commensal | Weak | 512 | 0.12 | 0.03 | 0.5 | 16 | 0.12 | 0.12 | 0.25 | This study |
| c2188_B | Commensal | Moderate | 512 | 0.12 | 0.03 | 0.5 | 32 | 0.12 | 0.06 | 2 | This study | |
| c3336_B | Commensal | No | 4 | 1 | 0.06 | 128 | 512 | 0.12 | 0.03 | 1 | This study | |
| c3342_A | Commensal | Moderate | 2 | 1 | 0.12 | 128 | 8 | 0.25 | 0.12 | 0.25 | This study | |
| c3342_B | Commensal | High | 256 | 1 | 0.0075 | 128 | 64 | 0.25 | 0.12 | 1 | This study | |
| c3437_A | Commensal | Moderate | 6 | 2 | 0.015 | 128 | 256 | 0.25 | 0.06 | 2 | This study | |
| c3807_A | Commensal | No | 256 | 1 | 0.03 | 64 | 8 | 0.25 | 0.06 | 2 | This study | |
| STF2003-1256 | Clinical | Weak | 4 | 1 | 0.06 | 0.5 | 256 | 0.25 | 0.06 | 0.5 | Dre Martine Boulianne | |
| 2006-4758 | Clinical | Weak | 256 | 2 | 0.03 | 0.5 | 16 | 0.06 | 0.03 | 0.5 | Dre Martine Boulianne | |
| SHY07-383 | Clinical | High | 3 | 0.5 | 0.0019 | 0.5 | 8 | 0.015 | 0.03 | 0.015 | Dre Martine Boulianne | |
| CP4 | Clinical | Moderate | 1.5 | 0.5 | 0.06 | 1 | 8 | 1 | 0.25 | 2 | Dr. John F. Prescott | |
| JGS4143 | Clinical | Moderate | 8 | 2 | 0.015 | 1 | 32 | 0.5 | 0.06 | 1 | Dr. Glenn Songer | |
| Human | CCRI-16276 | Clinical | Moderate | 16 | 0.5 | 0.03 | 2 | 8 | 0.5 | 0.25 | 2 | Dr. Maurice Boissinot |
| ATCC 13124 | Clinical | Weak | 2 | 0.5 | 0.03 | 1 | 0.5 | 0.06 | 0.12 | 0.015 | ATCC | |
| Swine | FMV-CP4 | Clinical | Moderate | 0.75 | 1 | 0.06 | 2 | 8 | 0.5 | 0.12 | 2 | This study |
| FMV-CP23 | Commensal | No | 1 | 0.5 | 0.12 | 1 | 16 | 0.25 | 0.06 | 1 | This study | |
| FMV-CP71 | Commensal | No | 0.75 | 0.12 | 0.12 | 4 | 128 | 0.25 | 0.12 | 0.25 | This study | |
| 1285414 | Clinical | Moderate | 16 | 2 | 0.12 | 0.5 | 512 | 0.5 | 0.12 | 0.25 | This study | |
| 1304504 | Clinical | Moderate | 2 | 1 | 0.03 | 2 | 4 | 0.12 | 0.03 | 0.015 | This study | |
Viability (%) of C. perfringens strain ATCC 13124 in biofilm after 24 h incubation with antibiotics and anticoccidials alone or in combinations.
| Alone | Monensin | Salinomycin | Narasin | |
|---|---|---|---|---|
| Alone | 100 | 65.5 | 79.5 | 61.8 |
| Bacitracin | 74.2 | 74.4 | ||
| Virginiamycin | 70.5 | 72.1 | ||
| Tylosin | 69.1 | 77.8 |
Effect of subinhibitory concentrations of bacitracin on biofilm formation as analyzed by scanning laser confocal microscopy.
| Isolates | Total height (μm) | Matrix (μm) | Cells (μm) | |
|---|---|---|---|---|
| Increased biofilm | c1261_A | 35 | 18 | 17 |
| c1261_A + bacitracin | 60 | 40 | 20 | |
| c3807_A | 45 | 35 | 10 | |
| c3807_A + bacitracin | 75 | 40 | 35 | |
| c3437_A | 30 | 22 | 8 | |
| c3437_A + bacitracin | 80 | 50 | 30 | |
| SHY07-383 | 50 | 25 | 25 | |
| SHY07-383 + bacitracin | 55 | 20 | 35 | |
| Decreased biofilm | ATCC 13124 | 45 | 33 | 12 |
| ATCC 13124 + bacitracin | 40 | 23 | 17 | |
| FMV-CP23 | 60 | 35 | 25 | |
| FMV-CP23 + bacitracin | 35 | 20 | 15 |